New Triple-Drug attack shows promise against aggressive breast cancer
NCT ID NCT03820141
First seen Apr 28, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study tests whether adding an immunotherapy drug (durvalumab) to two standard HER2-targeted drugs (trastuzumab and pertuzumab) can shrink tumors more effectively in women with a specific, aggressive type of breast cancer called HER2-enriched. About 51 women with early-stage, hormone-receptor-negative breast cancer will receive the combination before surgery. The main goal is to see how many patients have little or no cancer remaining in the breast after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.